Bharat Biotech International Limited announced on Monday that Rotavac 5D, a variant of its Rotavac vaccine, has received “Prequalification” from the World Health Organization (WHO). Rotavac is used to prevent rotavirus, which causes severe diarrhea and vomiting, and is mostly found in babies and children.
“Today’s announcement is an important step to further strengthen and fulfil Bharat Biotech’s vision to address neglected diseases, and prevent infections that continue to affect millions in the developing world,” a statement from Suchitra Ella, the Hyderabad-based pharmaceutical firm’s Joint Managing Director, said.
Bharat Biotech developed Rotavac, a first-generation vaccine, in a partnership with the Government of India’s Department of Biotechnology. 16 other international partners were also involved in the project. In March 2016, India became the first country in Asia to launch an anti-rotavirus vaccine, doing so under the Universal Immunisation Program (UIP).
News Source : Mint
